ERYtech Pharma Positions Its Lead Product In Solid Tumors And Launches A Phase II Clinical Study In Pancreatic Cancer
1/7/2014 8:53:24 AM
LYON, France--(BUSINESS WIRE)--Regulatory News:
ERYTECH Pharma (Euronext Paris: FR0011471135 - ERYP), a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, provides an update on its development plans to broaden the scope of its lead product ERYASP into the large field of solid tumors and announces the launch of a Phase II study in pancreatic cancer.
Help employers find you! Check out all the jobs and post your resume.
comments powered by